Infection of primary neurons mediated by Nipah virus envelope proteins: Role of host target cells in antiviral action

Journal of Virology

Volumn 85, Issue 16, 2011, Pages 8422-8426

  Talekar, Aparna ^a   Pessi, Antonello ^b   Porotto, Matteo ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b PeptiPharma   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHOLESTEROL CONJUGATED PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GENETIC TRANSFECTION; IC 50; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL; NIPAH VIRUS; NIPAH VIRUS INFECTION; NONHUMAN; NOTE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; TARGET CELL; VIRAL TROPISM; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION;

NIPAH VIRUS; PARAINFLUENZA VIRUS;

EID: 79961196362     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00452-11     Document Type: Note

References (28)

1. Arnaud, L. T., N. Myeku, and M. E. Figueiredo-Pereira. 2009. Proteasomecaspase-cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells. J. Neurochem. 110:328-342.
2. Bonaparte, M. I., et al. 2005. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc. Natl. Acad. Sci. U. S. A. 102:10652-10657.
3. Chua, K. B., et al. 1999. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 354:1257-1259.
4. Counts, S. E., and E. J. Mufson. 2010. Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J. Neurochem. 113:649-660.
5. Freiberg, A. N., M. N. Worthy, B. Lee, and M. R. Holbrook. 2010. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J. Gen. Virol. 91:765-772.
6. Georges-Courbot, M. C., et al. 2006. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrob. Agents Chemother. 50:1768-1772.
7. Goh, K. J., et al. 2000. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N. Engl. J. Med. 342:1229-1235.
8. Gurley, E. S., et al. 2007. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg. Infect. Dis. 13:1031-1037.
9. Homaira, N., et al. 2010. Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007. Epidemiol. Infect. 138:1630-1636.
10. Kandimalla, K. K., O. G. Scott, S. Fulzele, M. W. Davidson, and J. F. Poduslo. 2009. Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. PLoS One 4:e4627.
11. Lo, M. K., and P. A. Rota. 2008. The emergence of Nipah virus, a highly pathogenic paramyxovirus. J. Clin. Virol. 43:396-400.
12. Luby, S. P., E. S. Gurley, and M. J. Hossain. 2009. Transmission of human infection with Nipah virus. Clin. Infect. Dis. 49:1743-1748.
13. Luo, S., H. Mizuta, and D. C. Rubinsztein. 2008. p21-activated kinase 1 promotes soluble mutant huntingtin self-interaction and enhances toxicity. Hum. Mol. Genet. 17:895-905.
14. Negrete, O. A., et al. 2005. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 436:401-405.
15. Negrete, O. A., et al. 2006. Two key residues in EphrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog. 2:e7.
16. Pernet, O., C. Pohl, M. Ainouze, H. Kweder, and R. Buckland. 2009. Nipah virus entry can occur by macropinocytosis. Virology 395:298-311.
17. Porotto, M., et al. 2007. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. J. Virol. 81:10567-10574.
18. Porotto, M., M. Fornabaio, G. E. Kellogg, and A. Moscona. 2007. A second receptor binding site on human parainfluenza virus type 3 hemagglutininneuraminidase contributes to activation of the fusion mechanism. J. Virol. 81:3216-3228.
19. Porotto, M., M. Murrell, O. Greengard, and A. Moscona. 2003. Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion. J. Virol. 77:3647-3654.
20. Porotto, M., et al. 2009. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. J. Virol. 83:5148-5155.
21. Porotto, M., et al. 2010. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog. 6(10):e1001168. doi:10.1371/journal.ppat.1001168.
22. Porotto, M., et al. 2009. Kinetic dependence of paramyxovirus entry inhibition. J. Virol. 83:6947-6951.
23. Porotto, M., et al. 2010. Viral entry inhibitors targeted to the membrane site of action. J. Virol. 84:6760-6768.
24. Rockx, B., et al. 2010. A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J. Virol. 84:9831-9839.
25. Wang, L., et al. 2001. Molecular biology of Hendra and Nipah viruses. Microbes Infect. 3:279-287.
26. Wong, K. T. 2000. Emerging and re-emerging epidemic encephalitis: a tale of two viruses. Neuropathol. Appl. Neurobiol. 26:313-318.
27. Yonezawa, A., M. Cavrois, and W. C. Greene. 2005. Studies of Ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J. Virol. 79:918-926.
28. Zhou, X., X. W. Dong, and T. Priestley. 2006. The neuroleptic drug, fluphenazine, blocks neuronal voltage-gated sodium channels. Brain Res. 1106: 72-81.